Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
Public ClinicalTrials.gov record NCT02514213. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.
Study identification
- NCT ID
- NCT02514213
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 62 participants
Conditions and interventions
Conditions
Interventions
- 2mg INO-5150 and electroporation device CELLECTRA®-5P Biological
- 8.5mg INO-5150 and electroporation device CELLECTRA®-5P Biological
- 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P Biological
- 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P Biological
- Electroporation using CELLECTRA®-5P Device
Biological · Device
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2015 (Type not available)
- Primary completion
- Dec 12, 2017 (Actual)
- Completion
- Dec 12, 2017 (Actual)
- Last update posted
- Dec 26, 2017
2015 – 2017
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Chesapeake Urology Research Associates | Baltimore | Maryland | 21204 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| GU Research Network, LLC/ Urology Cancer Center | Omaha | Nebraska | 68130 | — |
| Weill Cornell Medical College | New York | New York | 10065 | — |
| University of North Carolina Lineberger Cancer Center | Chapel Hill | North Carolina | 27599 | — |
| Cleveland Clinic | Cleveland | Ohio | 44915 | — |
| Sidney Kimmel Cancer Center - Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| UPMC | Pittsburgh | Pennsylvania | 15232 | — |
| Carolina Urologic Research Center | Myrtle Beach | South Carolina | 29572 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02514213, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 26, 2017 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02514213 live on ClinicalTrials.gov.